Okano Yusuke, Kuramochi Hidekazu, Nakajima Go, Katagiri Satoshi, Yamamoto Masakazu
Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Shunjukuku, Tokyo 162-8666, Japan.
Department of Chemotherapy and Palliative Care, Tokyo Women's Medical University, Shunjukuku, Tokyo 162-8666, Japan.
Oncol Lett. 2017 Jul;14(1):930-936. doi: 10.3892/ol.2017.6241. Epub 2017 May 24.
Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) are associated with the response of tumors to fluoropyrimidines. The aim of the present study was to investigate the association between the levels of and mRNAs and the efficacy of S-1 for treating patients with HCC. A total of 35 patients with HCC who received S-1 upon recurrence (S-1 group) and 20 patients who never received a fluoropyrimidine (control group) were studied. The levels of and mRNA in surgically resected specimens were determined using reverse transcription-polymerase chain reaction assays. Overall survival (OS) time of S-1 group patients with high levels of mRNA was significantly longer compared with that of patients with low levels (median 501 days vs. 225 days; P=0.016). Similarly, the OS time of those patients with high levels of mRNA was significantly longer compared with those with low levels (median 503 days vs. 239 days; P=0.0076). By contrast, there was no difference in OS time of the control group between patients with high and low levels of and mRNAs. The levels of and mRNAs may serve as predictive markers for patients with HCC who receive S-1 chemotherapy.
胸苷酸合成酶（TYMS）和二氢嘧啶脱氢酶（DPYD）与肿瘤对氟嘧啶的反应相关。本研究的目的是探讨TYMS和DPYD mRNA水平与S-1治疗肝癌患者疗效之间的关联。共研究了35例复发时接受S-1治疗的肝癌患者（S-1组）和20例从未接受过氟嘧啶治疗的患者（对照组）。采用逆转录-聚合酶链反应法检测手术切除标本中TYMS和DPYD mRNA的水平。TYMS mRNA水平高的S-1组患者的总生存期（OS）明显长于水平低的患者（中位数501天对225天；P=0.016）。同样，DPYD mRNA水平高的患者的OS时间明显长于水平低的患者（中位数503天对239天；P=0.0076）。相比之下，对照组中TYMS和DPYD mRNA水平高和低的患者的OS时间没有差异。TYMS和DPYD mRNA水平可作为接受S-1化疗的肝癌患者的预测标志物。
